for everyone. joining and us Dan, Thanks good today. morning, Thanks,
our and Neoantigen Therapy Neoantigen GEN-XXX, to advance therapy programs by highlighted Candidate cell continue Vaccine Candidate. We and GEN-XXX, our Adoptive our vaccine Cell
As antigen things: here we at targets matter immunotherapy antigen-selection months under-appreciated Genocea, that target continue the have or plays first, and Atlas, work selection differently large body platform, than driving over works we two first-generation the peers. amassed and we XX that past of The in approaches demonstrates say our a efficacy. of to machine-based believe role our
prioritized importantly, more tools. and We neoantigens matter. Second, the identified we prospectively differences these of very by prove are believe those overlap being able with little Atlas cusp to on that first-generation
clinical from checkpoint With we clinical type. announced a the we with to Phase ongoing As patient's X/Xa at inhibitor plus GEN-XXX, this patients for our immunogenicity approved the we standard-of-care morning, trial positive plan ASCO. cancer to treat data that Phase have the of data, trial tumor X/Xa report first combination expand would
In and events we Duvall other activities briefly welcomed now me our last Let our as Diantha summarize March, update. since new CFO.
from the showcased a for month. just Cancer in data identification. moment. some the or this We You'll presented a Atlas hear These for Association Atlas beyond meeting Diantha of Research earlier data application American potential neoantigen AACR new at
of only ratio antigens checkpoint melanoma suggesting patients sharing effect AACR inhibitor advanced could suggested also the antigens. calling antigens We what of presentations that systematically to antigens. inhibitory from patient's immunosuppressive broad both such therapy. a inhibitory we predict anti-tumor identifies Atlas responses begun The a stimulatory data believe my that of and know, benefit these you As recently have identify and we can we're
to quarter over call to an the first for we're our in investment cell IND Diantha? the up the to our summarize to pass before continues, therapy going to financials XXXX. the file in adoptive aiming half Finally, of the program neoantigen for questions. I'm our call GEN-XXX, Diantha and opening now
